• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

    5/6/21 4:01:00 PM ET
    $KDMN
    Major Pharmaceuticals
    Health Care
    Get the next $KDMN alert in real time by email

    NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021.

    "We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA goal date of August 30, 2021. Labeling discussions with the FDA are progressing and we believe that belumosudil, if approved, will serve a critical, unmet need for patients with cGVHD," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "In addition, we are exploring the therapeutic potential of belumosudil in systemic sclerosis, a disease with similar manifestations to cGVHD. We continue to enroll patients in two separate Phase 2 studies in this indication and expect to present initial data from the open-label study by year-end 2021. In parallel, we are advancing the ongoing Phase 1 clinical trial of KD033, our anti-PD-L1/IL-15 fusion protein. We look forward to sharing initial safety data from this trial at ASCO in June 2021 and additional clinical data in the fourth quarter of 2021."

    2021 Anticipated Key Clinical Milestones:

    Belumosudil in chronic graft-versus-host disease (cGVHD)

    • Continue commercial launch readiness activities in anticipation of the Prescription Drug User Fee Act (PDUFA) goal date of August 30, 2021

    Belumosudil in diffuse subcutaneous systemic sclerosis (dcSSc)

    • Continue enrollment in the open-label Phase 2 clinical trial of belumosudil in patients with dcSSc (KD025-215); the Company plans to present initial data from the trial by year-end 2021
    • Continue enrollment in ongoing placebo-controlled Phase 2 clinical trial in dcSSc (KD025-209)

    KD033

    • Present initial safety data from the ongoing Phase 1 clinical trial of KD033, the Company's anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8, 2021; additional clinical data from the trial are expected to be available in Q4 2021
    • Enrollment in the first two dose cohorts of the KD033 Phase 1 trial (KD033-101) was successfully completed; enrollment is ongoing in the next dose level (cohort 3)

    Financial Results

    First Quarter 2021 Results

    Loss from operations for the three months ended March 31, 2021 was $27.4 million compared to $16.1 million for the same period in 2020, which included $6.0 million in one-time license revenues related to the Meiji strategic partnership.

    The $5.6 million increase in operating expenses for the three months ended March 31, 2021 as compared to 2020 was primarily related to belumosudil commercial launch readiness activities, as well as research and development costs for KD033 and our preclinical product candidates.

    Liquidity and Capital Resources

    At March 31, 2021, the Company's cash, cash equivalents and marketable debt securities totaled $295.9 million, compared to $123.9 million at December 31, 2020.

    About Belumosudil

    Belumosudil (KD025) is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a signaling pathway that modulates inflammatory response and pro-fibrotic processes. The FDA granted Priority Review for the New Drug Application (NDA) for belumosudil for the treatment of cGVHD and has assigned a PDUFA goal date of August 30, 2021. The NDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) and Project Orbis pilot programs. The FDA has granted Breakthrough Therapy Designation to belumosudil for the treatment of patients with cGVHD after failure of two or more lines of systemic therapy. The FDA has also granted Orphan Drug Designation to belumosudil for the treatment of cGVHD and for the treatment of systemic sclerosis.

    About Kadmon

    Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Kadmon's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

    Forward Looking Statements

    This press release contains forward-looking statements. Such statements may be preceded by the words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Among those risks and uncertainties are risks related to market conditions, including market interest rates, and the trading price and volatility of Kadmon's common stock. We believe that these factors include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) the impact of the COVID-19 pandemic on our business, workforce, patients, collaborators and suppliers, including delays in anticipated timelines and milestones of our clinical trials and on various government agencies who we interact with and/or are governed by; (iv) our reliance on the success of our product candidates; (v) the timing or likelihood of regulatory filings and approvals, especially in light of the COVID-19 pandemic; (vi) the benefits of FDA designations such as Breakthrough Therapy, and review of our NDA under the FDA's Oncology Center of Excellence pilot program, RTOR, and the FDA's Project Orbis initiative; (vii) our ability to expand our sales and marketing capabilities; (viii) the commercialization, pricing and reimbursement of our product candidates, if approved; (ix) the implementation of our business model, strategic plans for our business, product candidates and technology; (x) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (xi) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xii) costs associated with defending intellectual property infringement, product liability and other claims; (xiii) regulatory developments in the United States, Europe, and other jurisdictions; (xiv) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xvi) our ability to maintain and establish collaborations; (xvii) the rate and degree of market acceptance of our product candidates, if approved; (xviii) developments relating to our competitors and our industry, including competing therapies; (xix) our ability to effectively manage our anticipated growth; (xx) our ability to attract and retain qualified employees and key personnel; (xxi) our expected use of cash and cash equivalents and other sources of liquidity; (xxii) our expected use for the proceeds from the offering of our convertible senior notes; (xxiii) the potential benefits of any of our product candidates being granted orphan drug designation; (xxiv) the future trading price of the shares of our common stock and impact of securities analysts' reports on these prices; (xxv) our ability to apply unused federal and state net operating loss carryforwards against future taxable income and/or (xvi) other risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including Kadmon's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and Quarterly Report on Form 10-Q for the fiscal year ended March 31, 2021. Investors and security holders are urged to read these documents free of charge on the SEC's website at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

    Kadmon Holdings, Inc.
    Consolidated Statements of Operations - Unaudited
    (in thousands, except share and per share data)
    Three Months Ended
    March 31,
    2021 2020
    Revenues
    Net sales
    $360 $589
    Other revenue
    203 6,146
    Total revenue
    563 6,735
    Cost of sales
    96 328
    Write-down of inventory
    - 284
    Gross profit
    467 6,123
    Operating expenses:
    Research and development
    15,274 12,874
    Selling, general and administrative
    12,596 9,366
    Total operating expenses
    27,870 22,240
    Loss from operations
    (27,403) (16,117)
    Total other expense
    (975) (13,180)
    Income tax expense
    - -
    Net loss
    $(28,378) $(29,297)
    Deemed dividend on convertible preferred stock
    543 517
    Net loss attributable to common stockholders
    $(28,921) $(29,814)
    Basic and diluted net loss per share of common stock
    $(0.17) $(0.19)
    Weighted average basic and diluted shares of common stock outstanding
    171,689,510 158,031,405

    Kadmon Holdings, Inc.
    Condensed Consolidated Balance Sheets - Unaudited
    (in thousands)
    March 31, December 31,
    2021 2020
    Cash, cash equivalents and marketable debt securities
    $295,898 $123,858
    Other current assets
    4,738 2,879
    Investment, equity securities
    10,069 10,564
    Right of use lease asset
    15,204 16,112
    Other noncurrent assets
    9,198 9,297
    Total assets
    $335,107 $162,710
    Current liabilities
    28,255 29,471
    Lease liability - noncurrent
    14,479 15,579
    Other long term liabilities
    233,169 1,637
    Total liabilities
    275,903 46,687
    Total stockholders' equity
    59,204 116,023
    Total liabilities and stockholders' equity
    $335,107 $162,710


    Contact Information:

    Ellen Cavaleri, Investor Relations
    646.490.2989
    [email protected]

    SOURCE: Kadmon Holdings, Inc.



    View source version on accesswire.com:
    https://www.accesswire.com/645119/Kadmon-Provides-Business-Update-and-Reports-First-Quarter-2021-Financial-Results

    Get the next $KDMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KDMN

    DatePrice TargetRatingAnalyst
    9/14/2021$13.00 → $9.50Buy → Neutral
    Mizuho
    9/9/2021$10.00 → $9.50Buy → Hold
    Jefferies
    7/19/2021$8.00 → $9.00Outperform
    Oppenheimer
    More analyst ratings